Premium
Use of HBV Vaccine in Hemophiliacs
Author(s) -
Gazengel C.,
Courouce A.M.,
Torchet M.F.,
Kremp O.,
Brangier J.,
Brechot C.,
Degos F.
Publication year - 1984
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1984.tb02580.x
Subject(s) - medicine , hbsag , antibody , titer , gastroenterology , confidence interval , alanine transaminase , transaminase , hepatitis b virus , hepatitis b vaccine , immunology , virus , biology , biochemistry , enzyme
Patients with coagulation defects received three monthly injections of vaccine against Hepatitis B surface antigen (HEVAC B from Institut Pasteur Production, France). We now report preliminary results obtained in 26 hemophiliacs and in 7 patients with other coagulation defects. Very few side effects were observed. Immune response (anti HBs antibody 5–50 mIU/ml) was obtained in 32 patients (97 percent). The geometric mean of anti HBs titer one month after the 3rd injection of vaccine was 2,014 mIU/ml (95 percent confidence interval 1,195 to 3,331 mIU/ml) in 28 patients. Transaminase activity (ALT) was assayed in 31 patients: in 16 it was within normal limits (> 43 IU/L), a subsequent ALT increase was observed in 4. In the 15 other patients ALT was high at the beginning and did not change during the follow‐up. Neither HBsAg nor anti HBc (except for one patient with a low anti HBc level after F IX infusion) was detected. HBV‐DNA assay in the serum performed in patients with abnormal ALT activity, was negative.